CY1125292T1 - 6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER - Google Patents

6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER

Info

Publication number
CY1125292T1
CY1125292T1 CY20221100160T CY221100160T CY1125292T1 CY 1125292 T1 CY1125292 T1 CY 1125292T1 CY 20221100160 T CY20221100160 T CY 20221100160T CY 221100160 T CY221100160 T CY 221100160T CY 1125292 T1 CY1125292 T1 CY 1125292T1
Authority
CY
Cyprus
Prior art keywords
therapeutic treatment
tetpaydp
pypazolo
cancer
derivatives useful
Prior art date
Application number
CY20221100160T
Other languages
Greek (el)
Inventor
James Stewart Scott
Bernard Christophe Barlaam
Bin Yang
Thomas Andrew MOSS
Samantha Jayne HUGHES
Johannes Wilhelmus Maria Nissink
Daniel Hillebrand O'DONOVAN
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1125292T1 publication Critical patent/CY1125292T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η προδιαγραφή αναφέρεται σε ενώσεις του Τύπου (Ι): και σε φαρμακευτικώς αποδεκτά άλατα αυτής, σε διαδικασίες και ενδιάμεσες ενώσεις που χρησιμοποιούνται για την παρασκευή τους, σε φαρμακευτικές συνθέσεις που τις περιέχουν και στη χρήση τους στη θεραπευτική αντιμετώπιση των κυτταρικών πολλαπλασιαστικών διαταραχών.The specification refers to compounds of Formula (I): and pharmaceutically acceptable salts thereof, to processes and intermediate compounds used for their preparation, to pharmaceutical compositions containing them and to their use in the therapeutic treatment of cell proliferative disorders.

CY20221100160T 2016-10-24 2022-02-23 6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER CY1125292T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662411799P 2016-10-24 2016-10-24
US201662435159P 2016-12-16 2016-12-16
EP17783857.0A EP3433256B1 (en) 2016-10-24 2017-10-13 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer
PCT/EP2017/076191 WO2018077630A1 (en) 2016-10-24 2017-10-13 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1125292T1 true CY1125292T1 (en) 2024-02-16

Family

ID=60083331

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101110T CY1122566T1 (en) 2016-10-24 2019-10-24 6,7,8,9-TETPAYDP-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
CY20221100160T CY1125292T1 (en) 2016-10-24 2022-02-23 6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191101110T CY1122566T1 (en) 2016-10-24 2019-10-24 6,7,8,9-TETPAYDP-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER

Country Status (35)

Country Link
US (4) US10131663B2 (en)
EP (2) EP3640251B1 (en)
JP (2) JP6744489B2 (en)
KR (1) KR102178692B1 (en)
CN (2) CN114656464A (en)
AU (1) AU2017349797B2 (en)
BR (1) BR112019007393A2 (en)
CA (1) CA3040040A1 (en)
CL (1) CL2019001077A1 (en)
CO (1) CO2019003950A2 (en)
CR (1) CR20190204A (en)
CY (2) CY1122566T1 (en)
DK (2) DK3640251T3 (en)
DO (1) DOP2019000104A (en)
EC (1) ECSP19028657A (en)
ES (2) ES2751902T3 (en)
HR (1) HRP20220255T1 (en)
HU (2) HUE045714T2 (en)
IL (1) IL266245B (en)
JO (1) JOP20190090B1 (en)
LT (2) LT3640251T (en)
ME (1) ME03547B (en)
MX (1) MX2019004685A (en)
NI (1) NI201900039A (en)
NZ (1) NZ753459A (en)
PE (1) PE20191078A1 (en)
PH (1) PH12019500830A1 (en)
PL (2) PL3433256T3 (en)
PT (2) PT3433256T (en)
RS (1) RS59445B1 (en)
SG (1) SG11201903182XA (en)
SI (2) SI3640251T1 (en)
TW (1) TWI735681B (en)
UA (1) UA125824C2 (en)
WO (1) WO2018077630A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US9969732B2 (en) * 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (en) 2016-04-20 2018-02-01 阿斯特捷利康公司 Chemical compounds
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
MX2019004685A (en) 2016-10-24 2019-08-21 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer.
JOP20190144A1 (en) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the jak family of kinases
TWI831738B (en) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
RS63500B1 (en) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
JOP20190183B1 (en) 2017-01-30 2022-09-15 Astrazeneca Ab Estrogen receptor modulators
WO2019002442A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab Chemical compounds
WO2019002441A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab Chemical compounds
CA3082276C (en) * 2017-11-14 2022-08-16 Anlin Pharmaceuticals, Llc Heterocyclic compounds and their application in medicine
TW202016110A (en) 2018-06-15 2020-05-01 比利時商健生藥品公司 Small molecule inhibitors of the jak family of kinases
US11993574B2 (en) 2018-06-15 2024-05-28 Reata Pharmaceuticals, Inc Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma
AU2019321588A1 (en) 2018-08-17 2021-03-04 Genentech, Inc. Diagnostic and therapeutic methods for the treatment of breast cancer
CN109053524A (en) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 A kind of preparation method of N-Boc-3- hydroxy azetidine
CA3179912A1 (en) 2020-04-24 2021-10-28 Astrazeneca Ab Pharmaceutical formulations
WO2021214253A1 (en) * 2020-04-24 2021-10-28 Astrazeneca Ab Dosage regimen for the treatment of cancer
EP4151636A4 (en) 2020-05-15 2024-02-28 Simcere pharmaceutical co ltd Pyrrolidine compound and use thereof
CN115697987A (en) * 2020-06-12 2023-02-03 江苏先声药业有限公司 Estrogen receptor modulator compounds and uses thereof
WO2022001971A1 (en) * 2020-06-28 2022-01-06 南京明德新药研发有限公司 Indazole-fused cyclic compound
CN114105977B (en) * 2020-08-28 2023-09-01 先声再明医药有限公司 Estrogen receptor modulator compounds and uses thereof
KR20220107752A (en) 2021-01-26 2022-08-02 충북대학교 산학협력단 Pyrazoloquinoline derivatives and their use as anticancer agents
CN116669729A (en) * 2021-02-08 2023-08-29 贝达药业股份有限公司 Heteroaryl piperidine derivative, and pharmaceutical composition and application thereof
WO2023125700A1 (en) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 Salt form and crystal form of tetrahydrocyclohepta indazole compound
WO2024083716A1 (en) 2022-10-17 2024-04-25 Astrazeneca Ab Combinations of a serd for the treatment of cancer
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024105147A1 (en) 2022-11-17 2024-05-23 Astrazeneca Ab Methods of treatment of breast cancer with selective estrogen receptor degraders (serds)

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
BR0113176A (en) 2000-08-10 2003-06-17 Pharmacia Italia Spa Bicyclo-pyrazole compounds, pharmaceutical compositions comprising the compounds, use of the compounds in the manufacture of medicaments, processes for the preparation of the compounds, combinatorial chemical collection and methods for the treatment of mammals including humans using the compounds.
JP2008534496A (en) 2005-03-22 2008-08-28 アストラゼネカ・アクチエボラーグ Novel tetrahydro-1H-pyrido [4,3-b] indole derivatives as CB1 'receptor ligands
FR2884252B1 (en) 2005-04-08 2007-05-18 Aventis Pharma Sa NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF, IN PARTICULAR AS INHIBITORS OF CHAPERONE HSP90 PROTEIN ACTIVITY
AR058223A1 (en) 2005-11-25 2008-01-23 Palau Pharma Sa A COMMITTEE OF PIRAZOLOISOQUINOLINE DERIVATIVES, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOUND AND A PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20120157401A1 (en) 2009-05-27 2012-06-21 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
MX348817B (en) 2009-05-27 2017-06-30 Ptc Therapeutics Inc Methods for treating cancer and non-neoplastic conditions.
ES2627692T3 (en) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2012084711A1 (en) * 2010-12-24 2012-06-28 Msd Oss B.V. N-substituted azetidine derivatives
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
EP3004090B1 (en) 2013-05-28 2017-10-25 Astrazeneca AB Chemical compounds
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
MX2015017655A (en) 2013-06-19 2016-04-15 Seragon Pharmaceuticals Inc Estrogen receptor modulator and uses thereof.
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
JP6807841B2 (en) * 2014-12-18 2021-01-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Estrogen receptor modulator and its use
US9980947B2 (en) * 2014-12-18 2018-05-29 Genentech, Inc. Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
JP2017538727A (en) 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
WO2016202161A1 (en) * 2015-06-16 2016-12-22 江苏恒瑞医药股份有限公司 Piperidine derivative and preparation method and pharmaceutical use thereof
CN106518768B (en) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 Acrylic acid derivative, preparation method and medical application thereof
EP3912680A1 (en) 2015-10-01 2021-11-24 Olema Pharmaceuticals, Inc. Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
US10399939B2 (en) 2015-11-09 2019-09-03 Genentech, Inc. Tetrahydronaphthalene estrogen receptor modulators and uses thereof
CN107428758B (en) 2015-11-12 2020-08-04 浙江海正药业股份有限公司 Acrylic acid derivative, preparation method and medical application thereof
US10398689B2 (en) 2015-12-22 2019-09-03 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
US9969732B2 (en) 2016-04-08 2018-05-15 Genentech, Inc. Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
TW201803870A (en) * 2016-04-20 2018-02-01 阿斯特捷利康公司 Chemical compounds
WO2017182495A1 (en) * 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
CN109415361B (en) 2016-06-29 2022-03-08 浙江海正药业股份有限公司 Acrylic acid derivative, preparation method thereof and application thereof in medicine
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (en) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-substituted acrylic acid compound and preparation method and application thereof
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
BR102016024814A2 (en) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. Compound, Compounding Process, Pharmaceutical Composition, Compound Use, and Method of Treatment of Psychiatric Disorders and / or Sleep Disorders
MX2019004685A (en) * 2016-10-24 2019-08-21 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer.
PE20190977A1 (en) 2016-12-16 2019-07-09 Lilly Co Eli 7-PHENYLETHYLAMINE-4H-PYRIMID COMPOUNDS [4,5-D] [1,3] -OXAZIN-2-ONA AS INHIBITORS OF IDH1 AND IHD2 MUTANTS
JOP20190144A1 (en) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv Imidazopyrrolopyridine as inhibitors of the jak family of kinases
ES2934789T3 (en) 2016-12-16 2023-02-27 Pfizer glp-1 receptor agonists and uses thereof
TWI831738B (en) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
RS63500B1 (en) 2016-12-16 2022-09-30 Janssen Pharmaceutica Nv Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
RU2019121534A (en) 2016-12-16 2021-01-18 Басф Се PESTICIDAL COMPOUNDS
WO2018138293A1 (en) 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Tyrosine amide derivatives as rho- kinase inhibitors

Also Published As

Publication number Publication date
RS59445B1 (en) 2019-11-29
US10961241B2 (en) 2021-03-30
JP2019537570A (en) 2019-12-26
HUE045714T2 (en) 2020-01-28
HUE057524T2 (en) 2022-05-28
SI3640251T1 (en) 2022-04-29
CY1122566T1 (en) 2021-01-27
ES2751902T3 (en) 2020-04-02
ME03547B (en) 2020-07-20
EP3433256B1 (en) 2019-08-07
WO2018077630A1 (en) 2018-05-03
TW201829403A (en) 2018-08-16
CN109843888B (en) 2022-03-01
NZ753459A (en) 2023-01-27
HRP20220255T1 (en) 2022-04-29
AU2017349797B2 (en) 2020-05-21
KR20190066054A (en) 2019-06-12
BR112019007393A2 (en) 2019-07-02
CO2019003950A2 (en) 2019-04-30
US20210284636A1 (en) 2021-09-16
CR20190204A (en) 2019-06-11
JOP20190090A1 (en) 2019-04-23
CL2019001077A1 (en) 2019-06-21
IL266245B (en) 2021-05-31
US20190100520A1 (en) 2019-04-04
US20200239467A1 (en) 2020-07-30
SI3433256T1 (en) 2019-11-29
SG11201903182XA (en) 2019-05-30
DK3640251T3 (en) 2022-03-07
EP3640251A1 (en) 2020-04-22
EP3640251B1 (en) 2021-12-08
CN114656464A (en) 2022-06-24
DK3433256T3 (en) 2019-10-28
JP2020186250A (en) 2020-11-19
PT3433256T (en) 2019-10-31
NI201900039A (en) 2020-05-15
LT3433256T (en) 2019-11-11
LT3640251T (en) 2022-03-10
IL266245A (en) 2019-06-30
PH12019500830A1 (en) 2019-07-24
PL3640251T3 (en) 2022-04-11
US20180111931A1 (en) 2018-04-26
CA3040040A1 (en) 2018-05-03
US10590130B2 (en) 2020-03-17
UA125824C2 (en) 2022-06-15
JP6993477B2 (en) 2022-01-13
PL3433256T3 (en) 2020-01-31
US10131663B2 (en) 2018-11-20
ES2907759T3 (en) 2022-04-26
PE20191078A1 (en) 2019-08-20
ECSP19028657A (en) 2019-04-30
DOP2019000104A (en) 2019-05-15
EP3433256A1 (en) 2019-01-30
MX2019004685A (en) 2019-08-21
KR102178692B1 (en) 2020-11-13
CN109843888A (en) 2019-06-04
PT3640251T (en) 2022-02-22
JP6744489B2 (en) 2020-08-19
AU2017349797A1 (en) 2019-05-30
JOP20190090B1 (en) 2023-03-28
TWI735681B (en) 2021-08-11

Similar Documents

Publication Publication Date Title
CY1125292T1 (en) 6,7,8,9-TETPAYDP-3H-PYPAZOLO[4,3-F ISOQUINOLINE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
CY1123627T1 (en) DIHYDROIMIDAZOPYZINONE DERIVATIVES USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
CY1122730T1 (en) 1,2,4-TRIAZOLES AS NUCLEAR TRANSPORT MODULATORS AND THEIR USES
CY1119490T1 (en) PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT
CY1122966T1 (en) 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER
CY1125613T1 (en) 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AND 4- IMIDAZOTRIAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS
CY1124726T1 (en) QUINAZOLINE DERIVATIVES USED TO TREAT HIV
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
BR112015029455A8 (en) chemical compounds, use, methods and compositions for cancer prevention or treatment
CY1122731T1 (en) ESTROGEN RECEPTOR MODULATORS
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
MX2016003522A (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors.
TR201819805T4 (en) FLAVAGLIN DERIVATIVES.
EA201891027A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING INDOL DERIVATIVES, METHOD FOR ITS PREPARATION AND APPLICATION
EA201891680A1 (en) INDAN DERIVATIVES AS MGLUR7 MODULATORS
EA201792170A1 (en) INDOLA DERIVATIVES
EA201990943A1 (en) 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO [4,3-f] ISOCHINOLINE DERIVATIVES APPLICABLE IN TREATMENT OF CANCER
EA202092600A1 (en) TETRACYCLIC HETEROARYL COMPOUNDS
AR105921A1 (en) THERAPEUTIC COMPOUNDS FOR PAIN AND SYNTHESIS OF THESE